Table 1S. Univariate comparison of symptoms of patients with and without a history of SARS-CoV-2 infection, stratified by age and infection status

	All participants			Participants aged 5-11*			Participants aged 12-18*		
	No history of SARS-CoV2-infection	With a history of SARS-Cov-2 infection	P-value	No history of SARS-CoV2-infection	With a history of SARS-Cov-2 infection	P-value	No history of SARS-CoV2-infection	With a history of SARS-Cov-2 infection	P-value
	N= 2,092 n (%)	N= 1,148 n (%)		n=1218	n=815		N=817	N=224	
No reported symptoms	1396 (66.7)	646 (56.3)	<0.001	831 (68.2)	450 (55.2)	<0.001	508 (62.2)	88 (39.3)	<0.001
$\geq$ 1 symptom	696 (33.3)	502 (43.7)		387 (31.8)	365		309 (37.8)	136 (60.7)	

					(44.8)				
≥ 5 symptoms	89 (4.3)	114 (9.9)	<0.001	35 (2.9)	66 (8.1)	<0.001	54 (6.6)	48 (21.4)	<0.001
Current health status compared to before illness/pandemia worse	113 (5.4)	107 (9.3)	<0.001	47 (3.9)	64 (7.9)	<0.001	66 (8.1)	43 (19.2)	<0.001
Symptoms more prevalent in patients with a history of SARS-CoV-2 infection									
Headaches	114 (5.4)	211 (18.4)	<0.001	56 (4.6)	155 (19)	<0.001	58 (7.1)	56 (25%)	<0.001
Weakness	70 (3.3)	173 (15.1)	<0.001	27 (2.2)	112 (13.7)	<0.001	43 (5.3)	60 (26.8)	<0.001
Fatigue	133 (6.4)	141 (12.3)	<0.001	33 (2.7)	77 (9.4)	<0.001	100 (12.2)	64 (28.6)	<0.001
Abdominal pain	79 (3.8)	109 (9.5)	<0.001	49 (4)	87 (10.7)	<0.001	30 (3.7)	22 (9.8)	<0.001

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

BMJ Open

Cough	49 (2.3)	101 (8.8)	<0.001	32 (2.6)	73 (9)	<0.001	17 (2.1)	27 (12.1)	<0.001
Myalgia	47 (2.2)	99 (8.6)	<0.001	24 (2)	65 (8)	<0.001	23 (2.8)	34 (15.2)	<0.001
Decreased smell sensation	4 (0.2)	67 (5.8)	<0.001	1 (0.1)	31 (3.8)	<0.001	3 (0.4)	36 (16.1)	<0.001
Decreased taste sensation	2 (0.1)	60 (5.2)	<0.001	1 (0.1)	28 (3.4)	<0.001	1 (0.1)	32 (14.3)	<0.001
Nausea	43 (2.1)	51 (4.4)	<0.001	21 (1.7)	44 (5.4)	<0.001	22 (2.7)	7 (3.1)	0.818
Memory disturbances	18 (0.9)	51 (4.4)	<0.001	13 (1.1)	33 (4)	<0.001	5 (0.6)	18 (8)	<0.001
Dizziness	33 (1.6)	46 (4.0)	<0.001	11 (0.9)	26 (3.2)	<0.001	22 (2.7)	20 (8.9)	<0.001
Arthralgia	12 (0.6)	39 (3.4)	<0.001	6 (0.5)	24 (2.9)	<0.001	6 (0.7)	15 (6.7)	<0.001
Chest pain	13 (0.6)	31 (2.7)	<0.001	5 (0.4)	16 (2)	<0.001	8 (1)	15 (6.7)	<0.001
Dyspnea	20 (1)	31 (2.7)	<0.001	8 (0.7)	15 (1.8)	0.013	12 (1.5)	16 (7.1)	<0.001
Increased heart rate	14 (0.7)	23 (2.0)	<0.001	6 (0.5)	12 (1.5)	0.021	8 (1)	11 (4.9)	<0.001
Symptoms more prevalent in patients with no history of SARS-CoV-2 infection									

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

BMJ Open

Attention problems with school malfunctioning	225 (10.8)	98 (8.5)	0.05	133 (10.9)	68 (8.3)	0.057	92 (11.3)	30 (13.4)	0.412
Stress or increased worries	190 (9.1)	65 (5.7)	<0.001	112 (9.2)	48 (5.9)	0.007	78 (9.5)	17 (7.6)	0.433
Social problems	164 (7.8)	32 (2.8)	<0.001	87 (7.1)	20 (2.5)	<0.001	77 (9.4)	12 (5.4)	0.059
Weight changes	143 (6.8)	43 (3.7)	<0.001	71 (5.8)	25 (3.1)	0.004	72 (8.8)	18 (8)	0.789
Sleep disturbance	103 (4.9)	34 (3.0)	0.008	47 (3.9)	20 (2.5)	0.082	56 (6.9)	14 (6.3)	0.768
Symptoms with non-significant results									
Decreased mood	163 (7.8)	69 (6)	0.064	69 (5.7)	40 (4.9)	0.458	94 (11.5)	29 (12.9)	0.560
Rash	18 (0.9)	13 (1.1)	0.455	11 (0.9)	9 (1.1)	0.652	7 (0.9)	3 (1.3)	0.699
Visual disturbance	22 (1.1)	14 (1.2)	0.727	12 (1)	6 (0.7)	0.557	10 (1.2)	8 (3.6)	0.024
Hearing disturbances	7 (0.3)	0 (0)	0.056	4 (0.3)	0 (0)	0.102	3 (0.4)	0 (0)	0.602

*children whose parents did not declare age were excluded from the age stratification

Table 2S. Multivariate analysis of children with a history of SARS-CoV-2 infection who reported at least one symptom of long COVID-19

Variable	Odds Ratio (95% Confidence interval)	P value
Age †	1.08 (1.03, 1.14)	0.001
Sex (female) †	1.12 (0.84, 1.48)	0.442
Time from illness †	0.95 (0.86, 1.05)	0.311
Symptomatic COVID-19 †	4.41 (3.27, 5.94)	<0.001
Vaccination against COVID-19 †	0.87 (0.58, 1.31)	0.512

† Symptomatic disease, age, sex, time from illness, and vaccination status were entered with ENTER method
(*) The presence of diabetes mellitus, asthma, auto-immune disease, a history of malignancy, and native-born were entered with the FORWARD method. None were found significant and entered the final model.

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

BMJ Open

Table 3S. Multivariate analysis of children with a history of SARS-CoV-2 infection who reported their overall health state is worse than before the illness

Variable	Odds Ratio (95% Confidence interval)	P value
Age †	1.06 (0.96, 1.16)	0.257
Sex (female) †	1.06 (0.60, 1.88)	0.833
Time from illness †	0.94 (0.77, 1.16)	0.579
Symptomatic disease †	1.93 (0.93, 4.04)	0.079
Vaccination	1.25 (0.59, 2.65)	0.556
fatigue	9.71 (5.58, 16.87)	<0.001
Weight changes	4.75 (1.92, 11.76)	<0.001
Decreased social function	4.58 (1.64, 12.77)	0.004
Dyspnea ‡	3.35 (1.16, 9.63)	0.025
Increased stress	2.97 (1.37, 6.43)	0.006
Dizziness	2.75 (1.17, 6.49)	0.021
Headache ‡	2.70 (1.52, 4.80)	<0.001
Attention disturbances with impact on functioning in school	2.19 (1.12, 4.26)	0.022

†age, sex, time from illness, symptomatic disease, and vaccination status were entered with ENTER method
‡ Long COVID-19 symptoms (fatigue, decreased smell sensation, decreased taste sensation, headache, dyspnea, myalgia, cough, rash, nausea, weakness, depression, stress, memory disturbances, confusion, dizziness, sleep disturbances, arthralgia, abdominal pain, chest pain, increased heart rate, disturbed vision, hearing disturbances, weight changes, attention disturbances with impact on school and decreased social functioning) were entered with FORWARD method